Attached files
file | filename |
---|---|
EX-99.1 - TIENS BIOTECH GROUP USA INC | v207214_ex99-1.htm |
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 31,
2010
TIENS
BIOTECH GROUP (USA), INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-32477
|
75-2926439
|
||
(State
or other jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
||
of
incorporation)
|
Identification
Number)
|
No. 6, Yuanquan Road, Wuqing
New-Tech Industrial Park, Tianjin, China 301700
(Address
of principal executive offices)
Registrant's
telephone number, including area code:(86)22-8213-7335
Not
applicable
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Effective
as of December 31, 2010, Howard Balloch resigned from his position as Director
of Tiens Biotech Group (USA), Inc. (the “Company”). Mr. Balloch was a
member of the Audit Committee of the Board of Directors of the
Company. There were no disagreements between Mr. Balloch and the
Company on any matter relating to the Company’s operations, policies or
practices, which resulted in his resignation.
Mr.
Balloch’s resignation letter, dated as of December 21, 2010, is set forth in
Exhibit 99.1 attached hereto.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
|
Description
|
|
99.1
|
|
Resignation
Letter of Howard Balloch, dated December 21,
2010.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
TIENS
BIOTECH GROUP (USA), INC.
|
||
Date: January
4, 2011
|
By:
|
/s/ Jinyuan Li
|
Name: Jinyuan
Li
|
||
Title:
Chief Executive Officer
|
3
Exhibit
Index
Exhibit Number
|
Description
|
|
99.1
|
|
Resignation
Letter of Howard Balloch, dated December 21,
2010.
|
4